Previous 10 | Next 10 |
2023-12-11 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-11 06:20:03 ET AbbVie ( NYSE: ABBV ) and Genmab ( GMAB ) on Saturday presented latest trial data for their lymphoma drug candidate epcoritamab in patients with difficult-to-treat relapsed/refractory (R/R) follicular lymphoma (FL). Updated data from Phase 1/2 EPCO...
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) PR Newswire - Data from Phase 1/2 EPCORE™ NHL-1 study show patients tre...
Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcori...
2023-12-05 17:01:54 ET Gainers: Atea Pharmaceuticals ( AVIR ) +5% . The Lovesac Company ( LOVE ) +5% . MSP Recovery ( LIFW ) +4% . Huntington Bancshares ( HBANL ) +3% . Genmab ( GMAB ) +3% . Losers: Fluence En...
2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...
2023-11-27 08:03:06 ET More on AbbVie, Genmab, etc. AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks Genmab A/S (GMAB) Q3 2023 Earnings Call Transcript Genmab A/S 2023 Q3 - Results - Earnings Call Presentation AbbVie suing Sandoz, four others to block ...
U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy European Medicines Agency (EMA) validates regulatory applicatio...
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 8, 2023 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has inform...
2023-11-07 17:19:08 ET More on Genmab Genmab A/S (GMAB) Q3 2023 Earnings Call Transcript Genmab A/S 2023 Q3 - Results - Earnings Call Presentation Genmab Is Down To Attractive Levels Seagen, Genmab update Phase 3 data for uterine cancer therapy Genmab...
News, Short Squeeze, Breakout and More Instantly...
Genmab A/S Company Name:
GMAB Stock Symbol:
NYSE Market:
2024-06-04 10:00:04 ET Asthika Goonewardene from Truist Financial issued a price target of $53.00 for GMAB on 2024-06-04 08:14:00. The adjusted price target was set to $53.00. At the time of the announcement, GMAB was trading at $28.83. The overall price target consensus...
Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC, presented in a rapid oral session at 2024 ASCO ® Annual Meeting HNSCC is the sixth most common cancer worldwide, with inciden...